Blue­bird in fundrais­ing mode: A $150M pub­lic of­fer­ing and a deal to get cash ear­ly from gene ther­a­py sales

Last year
Financing
Deals

Com­pu­gen se­cures li­cens­ing deal with Gilead for IL-18 pro­tein an­ti­body can­cer pro­gram, with $60M up­front

Last year
Deals
R&D

Io­n­is di­vests com­mer­cial EU rights for rare dis­ease can­di­date to Ot­su­ka for $65M up­front

Last year
Deals
R&D

At least three dig­i­tal health star­tups will go pub­lic in 2024, Pitch­Book says

Last year
Health Tech

FDA broad­ens au­tho­riza­tion for Ak­il­i's video game for AD­HD

Last year
Pharma
FDA+

Organon adds Eli Lil­ly mi­graine meds to wom­en's health port­fo­lio in Eu­rope

Last year
Deals
Pharma

Ar­cutis scores FDA ap­proval for new foam treat­ment for com­mon skin con­di­tion

Last year
Pharma
FDA+

Atara Bio­ther­a­peu­tics to lay off 73 Cal­i­for­nia em­ploy­ees by the end of the year

Last year
R&D
Pharma

FDA fi­nal­izes opi­oid safe­ty la­bel­ing changes

Last year
Pharma
FDA+

Covid biotech’s stock jumps af­ter pos­i­tive ear­ly PhI­II mon­o­clon­al an­ti­body da­ta re­veal

Last year
R&D

Point Bio­phar­ma’s close­ly watched prostate can­cer ra­dio­phar­ma­ceu­ti­cal study dis­ap­points, Lil­ly again ex­tends of­fer

Last year
R&D

First Wave to merge with Im­muno­genX; Cali­way rais­es $100M; New deals for Re­play’s Sye­na

Last year
News Briefing

No­vo Nordisk Foun­da­tion to launch $260M vac­cine ini­tia­tive in ear­ly 2024

Last year
R&D
Manufacturing

Struc­ture’s oral GLP-1 a ‘work in progress’ fol­low­ing Phase IIa obe­si­ty and di­a­betes da­ta

Last year
R&D

FDA re­jects Check­point Ther­a­peu­tic­s' PD-L1 drug cosi­be­limab over man­u­fac­tur­ing is­sues

Last year
FDA+
Manufacturing

Bris­tol My­ers cuts PhI­II PD-1/LAG-3 tri­al in col­orec­tal can­cer short af­ter drug com­bo fails analy­sis

Last year
R&D
Pharma

Ex­clu­sive: A long­time VC takes on his own rare dis­ease as Sanofi, Boehringer com­mit $80M to launch new plat­form study

Last year
R&D

VC firm Piv­otal clos­es sec­ond $389M ther­a­peu­tics fund to cre­ate com­pa­nies and back pub­lic biotechs

Last year
Financing

Il­lu­mi­na to di­vest Grail, two years af­ter $8B deal was stymied by an­titrust is­sues

Last year
Diagnostics

Pfiz­er's tur­moil; FTC's new tar­get; Aviv Regev Q&A; As­traZeneca's vac­cine gam­bit; Best of #ASH23; and more

Last year
Weekly

Mer­ck­'s Welireg wins la­bel ex­pan­sion in kid­ney can­cer de­spite miss­ing sur­vival da­ta

Last year
Pharma
FDA+

FDA con­verts ac­cel­er­at­ed to full ap­proval for Pad­cev-Keytru­da com­bo in blad­der can­cer

Last year
Pharma
FDA+

Ab­b­Vie winds down five-year, $350M phil­an­thropy pledge

Last year
Pharma
Marketing

Eu­rope lines up first CRISPR ther­a­py ap­proval

Last year
Pharma
FDA+
First page Previous page 228229230231232233234 Next page Last page
A service from the Financial Times